GB Sciences, Inc.
GBLX · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $97 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $97 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $262 |
| G&A Expenses | $164 | $158 | $254 | $108 |
| SG&A Expenses | $164 | $158 | $254 | $108 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $164 | $158 | $254 | $370 |
| Operating Income | -$67 | -$158 | -$254 | -$370 |
| % Margin | -68.5% | – | – | – |
| Other Income/Exp. Net | -$34 | -$33 | -$31 | -$97 |
| Pre-Tax Income | -$100 | -$191 | -$285 | -$467 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$100 | -$191 | -$285 | -$467 |
| % Margin | -103.2% | – | – | – |
| EPS | -0 | -0.001 | -0.001 | -0.001 |
| % Growth | 60% | 28.6% | 41.7% | – |
| EPS Diluted | -0 | -0.001 | -0.001 | -0.001 |
| Weighted Avg Shares Out | 407,071 | 407,071 | 406,566 | 396,729 |
| Weighted Avg Shares Out Dil | 407,071 | 407,071 | 406,566 | 396,729 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $34 | $33 | $31 | $97 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$66 | -$158 | -$254 | -$370 |
| % Margin | -68.3% | – | – | – |